SERPINF1 as a Cause of Osteogenesis I mperfecta Type V I - Osteogenesis Imperfecta - page 155

References
[1] Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteo-
genesis imperfecta. J Med Genet 1979;16(2):101-16.
[2] Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R.
Osteogenesis imperfecta type VI: a form of brittle bone disease
with a mineralization defect. J Bone Miner Res 2002;17(1):30-8.
[3] Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis
imperfecta: a new form of brittle bone disease. J Bone Miner Res
2000;15(9):1650-8.
[4] Ward LM, Rauch F, Travers R, et al. Osteogenesis imperfecta type
VII: an autosomal recessive form of brittle bone disease. Bone
2002;31(1):12-18.
[5] Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM.
Classiication of osteogenesis imperfecta revisited. Eur J Med
Genet 2010;53(1):1-5.
[6] Becker J, Semler O, Gilissen C, et al. Exome sequencing identiies
truncating mutations in human SERPINF1 in autosomal-recessive
osteogenesis imperfecta. Am J Hum Genet 2011;88(3):362-71.
[7] Homan EP, Rauch F, Grafe I, et al. Mutations in SERPINF1 cause
osteogenesis imperfecta type VI. J Bone Miner Res 2011;26(12):
2798-803.
[8] Shaheen R, Alazami AM, Alshammari MJ, et al. Study of autoso-
mal recessive osteogenesis imperfecta in Arabia reveals a novel
locus deined by TMEM38B mutation. J Med Genet 2012;49(10):
630-5.
[9] Tucker T, Nelson T, Sirrs S, et al. A co-occurrence of osteo-
genesis imperfecta type VI and cystinosis. Am J Med Genet A
2012;158A(6):1422-6.

[21] Cao W, Tombran-Tink J, Chen W, Mrazek D, Elias R, McGinnis

JF. Pigment epithelium-derived factor protects cultured reti-
nal neurons against hydrogen peroxide-induced cell death.
J Neurosci Res 1999;57(6):789-800.

[22] Cao W, Tombran-Tink J, Elias R, Sezate S, Mrazek D, McGinnis

JF. In vivo protection of photoreceptors from light damage by
pigment epithelium-derived factor. Invest Ophthalmol Vis Sci
2001;42(7):1646-52.

[23] DeCoster MA, Schabelman E, Tombran-Tink J, Bazan NG.

Neuroprotection by pigment epithelial-derived factor against
glutamate toxicity in developing primary hippocampal neurons.
J Neurosci Res 1999;56(6):604-10.

[24] Bilak MM, Corse AM, Bilak SR, Lehar M, Tombran-Tink J, Kuncl

RW. Pigment epithelium-derived factor (PEDF) protects motor
neurons from chronic glutamate-mediated neurodegeneration.
J Neuropathol Exp Neurol 1999;58(7):719-28.

[25] Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-

derived factor: a potent inhibitor of angiogenesis. Science 1999;
285(5425):245-8.

[26] Phung MW, Dass CR. In-vitro and in-vivo assays for angio-

genesis-modulating drug discovery and development. J Pharm
Pharmacol 2006;58(2):153-60.

[27] Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived

factor inhibits retinal and choroidal neovascularization. J Cell
Physiol 2001;188(2):253-63.

[28] Raisler BJ, Berns KI, Grant MB, Beliaev D, Hauswirth WW.

Adeno-associated virus type-2 expression of pigmented epithe-
lium-derived factor or Kringles 1-3 of angiostatin reduce retinal
neovascularization. Proc Natl Acad Sci U S A 2002;99(13):8909-14.

[10] Rauch F, Husseini A, Roughley P, Glorieux FH, Moffatt P. Lack

of circulating pigment epithelium-derived factor is a marker
of osteogenesis imperfecta type VI. J Clin Endocrinol Metab
2012;97(8):E1550-6.

[29] Auricchio A, Behling KC, Maguire AM, et al. Inhibition of reti-

nal neovascularization by intraocular viral-mediated delivery of
anti-angiogenic agents. Mol Ther 2002;6(4):490-4.

[30] Longeras R, Farjo K, Ihnat M, Ma JX. A PEDF-derived peptide

inhibits retinal neovascularization and blocks mobilization of
bone marrow-derived endothelial progenitor cells. Exp Diabetes
Res 2012;2012:518426.

[11] Venturi G, Gandini A, Monti E, et al. Lack of expression of

SERPINF1, the gene coding for pigment epithelium-derived
factor, causes progressively deforming osteogenesis imperfecta
with normal type I collagen. J Bone Miner Res 2012;27(3):723-8.

[31] Manalo KB, Choong PF, Dass CR. Pigment epithelium-derived

factor as an impending therapeutic agent against vascular epi-
thelial growth factor-driven tumor-angiogenesis. Mol Carcinog
2011;50(2):67-72.

[12] Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imper-

fecta type VI in childhood and adolescence: effects of cyclical
intravenous pamidronate treatment. Bone 2007;40(3):638-44.

[13] Cummings SR, San Martin J, McClung MR, et al. Denosumab

for prevention of fractures in postmenopausal women with
osteoporosis. N Engl J Med 2009;361(8):756-65.

[32] Fitzgerald DP, Subramanian P, Deshpande M, et al. Opposing

effects of pigment epithelium-derived factor on breast cancer
cell versus neuronal survival: implication for brain metasta-
sis and metastasis-induced brain damage. Cancer Res 2012;
72(1):144-53.

[14] Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P,

Schoenau E. First use of the RANKL antibody denosumab in
osteogenesis imperfecta type VI. J Musculoskelet Neuronal
Interact 2012;12(3):183-8.

[33] Crowe S, Wu LE, Economou C, et al. Pigment epithelium-

derived factor contributes to insulin resistance in obesity. Cell
Metab 2009;10(1):40-7.

[15] Ek ET, Dass CR, Choong PF. PEDF: a potential molecular thera-

peutic target with multiple anti-cancer activities. Trends Mol
Med 2006;12(10):497-502.

[34] Famulla S, Lamers D, Hartwig S, et al. Pigment epithelium-

derived factor (PEDF) is one of the most abundant proteins
secreted by human adipocytes and induces insulin resistance and
inlammatory signaling in muscle and fat cells. Int J Obes 2011;
35(6):762-72.

[16] Rychli K, Huber K, Wojta J. Pigment epithelium-derived factor

(PEDF) as a therapeutic target in cardiovascular disease. Expert
Opin Ther Targets 2009;13(11):1295-302.

[17] Quan GM, Ojaimi J, Li Y, Kartsogiannis V, Zhou H, Choong PF.

Localization of pigment epithelium-derived factor in growing
mouse bone. Calcif Tissue Int 2005;76(2):146-53.

[35] Ogata N, Matsuoka M, Matsuyama K, et al. Plasma concentra-

tion of pigment epithelium-derived factor in patients with dia-
betic retinopathy. J Clin Endocrinol Metab 2007;92(3):1176-9.

[18] Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment

epithelium-derived factor with potent neuronal differentiative
activity. Exp Eye Res 1991;53(3):411-4.

[36] Jenkins A, Zhang SX, Gosmanova A, et al. Increased serum

pigment epithelium derived factor levels in Type 2 diabetes
patients. Diabetes Res Clin Pract 2008;82(1):e5-e7.

[19] Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epi-

thelium-derived factor: neurotrophic activity and identiication
as a member of the serine protease inhibitor gene family. Proc
Natl Acad Sci USA 1993;90(4):1526-30.

[37] Yamagishi S, Adachi H, Abe A, et al. Elevated serum levels of

pigment epithelium-derived factor in the metabolic syndrome.
J Clin Endocrinol Metab 2006;91(6):2447-50.

[38] Wang P, Smit E, Brouwers MC, et al. Plasma pigment epithelium-

derived factor is positively associated with obesity in Caucasian
subjects, in particular with the visceral fat depot. Eur J Endocrinol
2008;159(6):713-8.

[20] Becerra SP. Structure-function studies on PEDF. A noninhibitory

serpin with neurotrophic activity. Adv Exp Med Biol 1997;425:
223-37.